CRIDANIMOD

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H11NO3
Molecular Weight	253.2527
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN1C2=C(C=CC=C2)C(=O)C3=C1C=CC=C3

InChI

InChIKey=UOMKBIIXHQIERR-UHFFFAOYSA-N

InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H11NO3
Molecular Weight	253.2527
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02064725 | https://clinicaltrials.gov/ct2/show/NCT03077698

Cridanimod (Virexxa) is a small-molecule immunomodulator and interferon inducer, which, in preliminary studies, has been shown to increase progesterone receptor expression in endometrial tissue. Restoration of progesterone receptor expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Cridanimod was originally developed by Polysan and Pharmsynthez and licensed to Xenetic Biosciences. Virexxa is currently being studied in an ongoing Phase 2 multi-national study in conjunction with progestin therapy for the treatment of endometrial cancer in women with the recurrent or persistent disease who have failed progestin monotherapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
progesterone receptor signaling pathway 2 Target ID: GO:0050847 Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent or persistent endometrial carcinoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02064725	Primary		Phase II 1132	Unknown Approved Use Unknown
Endometrial cancer 43 Sources: https://clinicaltrials.gov/ct2/show/NCT03077698	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Pulmonary surfactant and blood serum in patients with chronic obstructive bronchitis on differentiated therapy].	2002 Apr-Jun	12145894
[Effect of interferon inductors on infection induced by hepatitis C virus and activity of mRNA cytokines in cell cultures SW-13 and MT-4].	2002 Nov-Dec	12508677
Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro.	2003 Apr	12742573
[Neuroimmunopathologic aspects of epilepsy].	2004	15455693
[The preclinical diagnosis, prevention and treatment of postoperative iridocyclitis in patients after intraocular aphakia correction].	2004 Jul-Aug	15384841
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections].	2004 Nov-Dec	15636140
[Cyclopheron pretreatment in opisthorchiasis management in patients with viral hepatitis C].	2005	16404860
[Individual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon].	2005 Mar-Apr	15881395
[Influence of cycloferon on the biological properties of bacterial intracellular pathogens].	2005 May-Jun	16028504
[Immunological and microbiological aspects of low intensity laser effect on the factors of local immunity of the reproductive tract in women with chlamydia infection].	2006 Jul-Aug	16941885
[Effect of aerosol therapy with cyclopheron in patients with chronic rhinitis].	2006 Jun	16905806
[Some pathogenic mechanisms of aerozol-therapy including cyclopheron treatment in patients with chronic rhinitis].	2006 May	16783061
[Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)].	2010	21341470
[Effectiveness of cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis].	2010	21207889
[Optimization of parodontitis treatment of patients with tuberculosis].	2010	21186645
[Changes of functional activity of peripheral blood leukocytes during the immunotherapy of tick-borne infections in children].	2010	21183923
[Cycloferon in complex therapy of chronic brucellosis].	2010	21140564
[Cycloferon efficacy in the treatment of acute respiratory tract viral infection and influenza during the morbidity outbreak in 2009-2010].	2010	20583555
[Clinical efficiency of the use of interferon inductors in surgical patients].	2010	20559225
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].	2010 Apr	20486553

Patents

Sample Use Guides

In Vivo Use Guide

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:13 GMT 2023` Edited by `admin` on `Fri Dec 15 16:18:13 GMT 2023`
Record UNII	X91E9EME19
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CRIDANIMOD

Official Name

English

Cridanimod [WHO-DD]

Common Name

English

cridanimod [INN]

Common Name

English

9-OXO-10-ACRIDANACETIC ACID

Systematic Name

English

10-(CARBOXYMETHYL)-9-ACRIDINONE

Systematic Name

English

10(9H)-ACRIDINEACETIC ACID, 9-OXO-

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

L03AX18